More pain likely for Divi's Laboratories

The Visakhapatnam plant under import alert contributes about 20% to company's overall sales

The worst fears of the Street came true as Divi’s Laboratories got an import alert from the US FDA for its Unit II at Visakhapatnam. The facility had been inspected by the FDA in end November and had received five observations. The observations were serious in nature and raised concerns about data integrity and quality control systems, said analysts. Nevertheless, the company said that it is making earnest efforts on compliance and also had filed its comprehensive response to the observations within the stipulated time. The matter, however, has escalated now with company’s facility being issued import alert leading to